The role of gut microbiota in paediatric short bowel syndrome.
4 affiliations
- 1Department of Paediatrics, Luzhou People's Hospital, Luzhou, China.
- 2Department of Paediatrics, Luxian People's Hospital, Luzhou, China.
- 3Department of Paediatrics, Children's Medical Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- 4Sichuan Clinical Research Center for Birth Defects, Luzhou, China.
Abstract
Short bowel syndrome (SBS) is one of the leading causes of intestinal failure in children. Its development is influenced not only by the length and function of the residual intestine but is also closely related to the homeostasis of the gut microbiota. In recent years, the role of the gut microbiota in intestinal adaptation, metabolic regulation, and the development of complications in pediatric SBS has gradually garnered attention. This review summarizes the characteristics of the gut microbiota, mechanisms underlying dysbiosis, associations with complications, and microbiota-targeted therapeutic strategies in pediatric SBS. Existing studies indicate that children with SBS exhibit reduced microbiota diversity, compositional abnormalities, and metabolic dysfunction. Gut microbiota dysbiosis may be associated with intestinal barrier disruption, immune dysregulation, alterations in residual intestinal structure, and parenteral nutrition, and may contribute to the development and progression of complications such as small intestinal bacterial overgrowth (SIBO), D-lactic acidosis (D-LA), and liver injury. Strategies such as probiotics, nutritional modulation, and fecal microbiota transplantation (FMT) have shown potential clinical value, although their efficacy and safety require further validation. Future studies integrating multi-omics approaches and long-term longitudinal investigations are needed to elucidate the mechanisms underlying interactions between the microbiota and host, thereby providing a theoretical basis for microbiota-targeted interventions and improving long-term outcomes in children with SBS.
Related
- Changes in Intestinal Microbiota Tracked Using Next-generation Sequencing Before and after Antimicrobial Administration: An Example of Short-bowel Syndrome
- Associations of colonic transit with the gut microbiota and short-chain fatty acids in health and irritable bowel syndrome.
- Gut microbiota–mediated tryptophan metabolic dysregulation in the comorbidity of inflammatory bowel disease and autism spectrum disorder: mechanisms and research progress
- Viral-Gut Microbiota Interactions: Implications for the Gut Mucosa in Inflammatory Bowel Disease.
- Microbiota-Associated Metabolites as Biomarkers and Therapeutic Opportunities in Inflammatory Bowel Disease
BibTeX
@article{zeng2026role,
title = {{The role of gut microbiota in paediatric short bowel syndrome.}},
author = {Cheng Zeng and Lidan Liang and Tingfang Lv},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1970119},
url = {https://europepmc.org/article/MED/42909301},
note = {CC BY},
}
RIS
TY - JOUR
TI - The role of gut microbiota in paediatric short bowel syndrome.
AU - Cheng Zeng
AU - Lidan Liang
AU - Tingfang Lv
PY - 2026
DA - 2026/10/07
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1970119
UR - https://europepmc.org/article/MED/42909301
AB - Short bowel syndrome (SBS) is one of the leading causes of intestinal failure in children. Its development is influenced not only by the length and function of the residual intestine but is also closely related to the homeostasis of the gut microbiota. In recent years, the role of the gut microbiota in intestinal adaptation, metabolic regulation, and the development of complications in pediatric SBS has gradually garnered attention. This review summarizes the characteristics of the gut microbiota, mechanisms underlying dysbiosis, associations with complications, and microbiota-targeted therapeutic strategies in pediatric SBS. Existing studies indicate that children with SBS exhibit reduced microbiota diversity, compositional abnormalities, and metabolic dysfunction. Gut microbiota dysbiosis may be associated with intestinal barrier disruption, immune dysregulation, alterations in residual intestinal structure, and parenteral nutrition, and may contribute to the development and progression of complications such as small intestinal bacterial overgrowth (SIBO), D-lactic acidosis (D-LA), and liver injury. Strategies such as probiotics, nutritional modulation, and fecal microbiota transplantation (FMT) have shown potential clinical value, although their efficacy and safety require further validation. Future studies integrating multi-omics approaches and long-term longitudinal investigations are needed to elucidate the mechanisms underlying interactions between the microbiota and host, thereby providing a theoretical basis for microbiota-targeted interventions and improving long-term outcomes in children with SBS.
SN - 2235-2988
ER -